AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026240271
Submit to EJMO
Cite this article
11
Download
91
Views
Related Info Links
Google Scholar
More by Authors Links
Yan Bo
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW ARTICLE

Primary ovarian insufficiency: Genetic etiology, in vitro follicle activation mechanisms, and clinical management perspectives

Yan Bo1* ,  Youwei Wang2
Show Less
1 Department of Medicine, Northwest Minzu University, Lanzhou, Gansu , China
2 School of Medicine, Beihua University, Jilin City, Jilin , China
EJMO, 026240271 https://doi.org/10.36922/EJMO026240271
Received: 12 June 2026 | Revised: 24 July 2026 | Accepted: 30 July 2026 | Published online: 17 September 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Introduction: Menstrual irregularities or amenorrhea affect at least 17.4 million women worldwide. Symptoms in young patients may be atypical, and imaging and serum hormone levels are sometimes insufficient to explain the condition.

Objectives: This review synthesizes current evidence to improve diagnostic and treatment strategies, reduce misdiagnosis of primary ovarian insufficiency (POI), facilitate timely treatment, and support earlier recognition and individualized follow-up to preserve reproductive function.

Methods: We conducted a narrative review of studies addressing the genetic basis, molecular mechanisms, follicular activation pathways, and clinical management of POI. Particular attention was given to single-gene variants, chromosomal abnormalities, phosphoinositide 3-kinase (PI3K), mechanistic target of rapamycin (mTOR), and Hippo signaling pathways, as well as acquired or functional conditions that may mimic genetic POI.

Results: POI is a heterogeneous reproductive endocrine disorder involving chromosomal abnormalities, X-linked factors, folliculogenesis-related genes, meiotic and chromosomal stability defects, and DNA damage repair pathways. Representative genes such as FMR1, BMP15, GDF9, NR5A1, HFM1, STAG3, and BRCA2 illustrate the diverse mechanisms that impair ovarian reserve or cause follicular dysfunction. In vitro activation of dormant follicles is biologically supported by PI3K/phosphatase and tensin homolog/protein kinase B/FOXO3a, mTOR, and Hippo signaling pathways, but its clinical application remains limited and requires further validation. Functional hypothalamic amenorrhea, drug exposure, metabolic abnormalities, endocrine tumors, and autoimmune conditions should also be considered in the differential diagnosis.

Conclusion: POI in young women should not be simply attributed to stress, emotional factors, or menstrual irregularity. Early etiological evaluation, appropriate genetic testing, differential diagnosis, reproductive counseling, hormone replacement therapy when indicated, fertility preservation planning, and long-term multidisciplinary follow-up may improve clinical management. In vitro activation-related mechanisms provide a potential biological rationale for future fertility-preserving strategies, but broader clinical use requires stronger evidence.

Keywords
In vitro activation of dormant follicles
Primary ovarian insufficiency
Therapeutic mechanism
Genetic etiology
Clinical management
Funding
None.
Conflict of interest
The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
References
  1. Saadedine M, Kapoor E, Shufelt C. Functional Hypothalamic Amenorrhea: Recognition and management of a challenging diagnosis. Mayo Clin Proc. 2023;98(9):1376-1385. doi: 10.1016/j.mayocp.2023.05.027
  2. Silvén H, Savukoski SM, Pesonen P, et al. Incidence and familial risk of premature ovarian insufficiency in the Finnish female population. Hum Reprod. 2022;37(5):1030-1036. doi: 10.1093/humrep/deac014
  3. Blümel JE, Mezones-Holguín E, Chedraui P, Soto-Becerra P, Arteaga E, Vallejo MS. Is premature ovarian insufficiency associated with mortality? A three-decade follow-up cohort. Maturitas. 2022;163:82-87. doi: 10.1016/j.maturitas.2022.06.002
  4. Federici S, Rossetti R, Moleri S, et al. Primary ovarian insufficiency: update on clinical and genetic findings. Front Endocrinol. 2024;15:1464803. doi: 10.3389/fendo.2024.1464803
  5. Nie L, Wang X, Wang S, Hong Z, Wang M. Genetic insights into the complexity of premature ovarian insufficiency. Reprod Biol Endocrinol. 2024;22(1):94. doi: 10.1186/s12958-024-01254-2
  6. Chen M, Jiang H, Zhang C. Selected Genetic Factors Associated with Primary Ovarian Insufficiency. Int J Mol Sci. 2023;24(5):4423. doi: 10.3390/ijms24054423
  7. Abujaber R, Henry-Smith C, Sharma S. From Genes to Lives: Integrating the complexities of primary ovarian insufficiency. Int J Mol Sci. 2026;27(3):1353. doi: 10.3390/ijms27031353
  8. Zhuang Z, Bo Y. Self-management and role of nurses of diabetic patients: a critical narrative literature review during COVID-19 pandemic. Front Med. 2025;12:1626447. doi: 10.3389/fmed.2025.1626447
  9. Bo Y, Zhao F. Platelets as central hubs of inflammation. Front Immunol. 2025;16:1683553. doi: 10.3389/fimmu.2025.1683553
  10. Bo Y. The role of inflammation in depression: a scoping review protocol in mechanisms, evidence, and therapeutic potential. Res Connect. 2026;1(1). doi: 10.1093/rescon/vmag006
  11. Bo Y. Psychotherapy combined with artificial liver support for acute-on-chronic liver failure with persistent fever and mania: a case report. Res Connect. 2026;1(1). doi: 10.1093/rescon/vmag001
  12. Nelson LM. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606-614. doi: 10.1056/nejmcp0808697
  13. Vujovic S. Aetiology of premature ovarian failure. Menopause Int. 2009;15(2):72-75. doi: 10.1258/mi.2009.009020
  14. Nguyen HH, Milat F, Vincent AJ. New insights into the diagnosis and management of bone health in premature ovarian insufficiency. Climacteric. 2021;24(5):481-490. doi: 10.1080/13697137.2021.1917539
  15. Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(2):178-186. doi: 10.1177/2047487314556004
  16. Panay N. Progress in understanding and management of premature ovarian insufficiency. Climacteric. 2021;24(5):423-424. doi: 10.1080/13697137.2021.1919460
  17. Kawamura K, Kawamura N, Hsueh AJW. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016;28(3):217-222. doi: 10.1097/gco.0000000000000268
  18. Panay N, Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol. 2009;23(1):129-140. doi: 10.1016/j.bpobgyn.2008.10.008
  19. Kalu E, Panay N. Spontaneous premature ovarian failure: Management challenges. Gynecol Endocrinol. 2008;24(5):273-279. doi: 10.1080/09513590801990764
  20. Liu FX, Sun Y. Identification of the active ingredients and pharmacological effects of Kuntai capsules in the treatment of primary ovarian insufficiency: A review. Medicine. 2023;102(21):e33884. doi: 10.1097/md.0000000000033884
  21. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376(9744):911-921. doi: 10.1016/s0140-6736(10)60355-8
  22. Li J, Kawamura K, Cheng Y, et al. Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci USA. 2010;107(22):10280-10284. doi: 10.1073/pnas.1001198107
  23. Takeuchi A, Koga K, Satake E, et al. Endometriosis triggers excessive activation of primordial follicles via PI3K-PTEN-Akt-Foxo3 pathway. J Clin Endocrinol Metab. 2019;104(11):5547-5554. doi: 10.1210/jc.2019-00281
  24. Fu Y, Ding DN, Shen Y, et al. Complementary and Alternative Medicine for Premature Ovarian Insufficiency: A Review of Utilization and Mechanisms. Evid Based Complement Alternat Med. 2022;2022:9053930. doi: 10.1155/2022/9053930
  25. Qin Y, Jiao X, Simpson JL, Chen ZJ. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update. 2015;21(6):787-808. doi: 10.1093/humupd/dmv036
  26. Bai X, Wang S. Signaling pathway intervention in premature ovarian failure. Front Med. 2022;9:999440. doi: 10.3389/fmed.2022.999440
  27. Grin L, Berkovitz-Shperling R, Goldstein G, et al. Drug-free in vitro activation of ovarian follicles and fresh tissue autotransplantation in patients with poor ovarian response and premature ovarian insufficiency. F S Sci. 2025;6(3):303-311. doi: 10.1016/j.xfss.2025.04.002
  28. Zhang L, Zhang J, Zhai J, et al. Autotransplantation of the ovarian cortex after in-vitro activation for infertility treatment: a shortened procedure. Hum Reprod. 2021;36(8):2134-2147. doi: 10.1093/humrep/deab143
  29. Lunding SA, Pors SE, Kristensen SG, et al. Biopsying, fragmentation and autotransplantation of fresh ovarian cortical tissue in infertile women with diminished ovarian reserve. Hum Reprod. 2019;34(10):1924-1936. doi: 10.1093/humrep/dez152
  30. Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 2015;11(7):1946-1954. doi: 10.1039/c5mb00101c
  31. Kim JY. Control of ovarian primordial follicle activation. Clin Exp Reprod Med. 2012;39(1):10-14. doi: 10.5653/cerm.2012.39.1.10
  32. Huhtaniemi I, Hovatta O, La Marca A, et al. Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol Metab. 2018;29(6):400-419. doi: 10.1016/j.tem.2018.03.010
  33. Adhikari D, Zheng W, Shen Y, et al. Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial follicles. Hum Mol Genet. 2010;19(3):397-410. doi: 10.1093/hmg/ddp483
  34. Zhang H, Risal S, Gorre N, et al. Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Curr Biol. 2014;24(21):2501-2508. doi: 10.1016/j.cub.2014.09.023
  35. Kawamura K, Cheng Y, Suzuki N, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci USA. 2013;110(43):17474-17479. doi: 10.1073/pnas.1312830110
  36. De Roo C, Lierman S, Tilleman K, De Sutter P. In-vitro fragmentation of ovarian tissue activates primordial follicles through the Hippo pathway. Hum Reprod Open. 2020;2020(4):hoaa048. doi: 10.1093/hropen/hoaa048
  37. Lourenço D, Brauner R, Lin L, et al. Mutations in NR5A1 Associated with Ovarian Insufficiency. N Engl J Med. 2009;360(12):1200-1210. doi: 10.1056/nejmoa0806228
  38. Allali S, Muller JB, Brauner R, et al. Mutation Analysis of NR5A1 Encoding Steroidogenic Factor 1 in 77 Patients with 46, XY Disorders of Sex Development (DSD) Including Hypospadias. PLoS One. 2011;6(10):e24117. doi: 10.1371/journal.pone.0024117
  39. Fabbri-Scallet H, Werner R, Guaragna MS, et al. Can Non-Coding NR5A1 gene variants explain phenotypes of disorders of sex development? Sex Dev. 2022;16(4):252-260. doi: 10.1159/000524956
  40. Zhe J, Chen S, Chen X, et al. A novel heterozygous splice-altering mutation in HFM1 may be a cause of premature ovarian insufficiency. J Ovarian Res. 2019;12(1):61. doi: 10.1186/s13048-019-0537-x
  41. Caburet S, Arboleda VA, Llano E, et al. Mutant cohesin in premature ovarian failure. N Engl J Med. 2014;370(10):943-949. doi: 10.1056/nejmoa1309635
  42. Weinberg-Shukron A, Rachmiel M, Renbaum P, et al. Essential role of BRCA2 in ovarian development and function. N Engl J Med. 2018;379(11):1042-1049. doi: 10.1056/nejmoa1800024
  43. Ludman MD, Philipsborn SL, Hartmajer S, Shwartzman NS, Reinstein E. Recurring pathogenic variants in the BRCA2 gene in the Ethiopian Jewish population. Founder mutations? Fam Cancer. 2022;21(2):121-123. doi: 10.1007/s10689-021-00255-z
  44. Christopoulos C, Dimakopoulou V, Rotas E. Primary Ovarian Insufficiency Associated with Imatinib Therapy. N Engl J Med. 2008;358(10):1079-1080. doi: 10.1056/nejmc0707841
  45. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34-74. doi: 10.1016/j.phrs.2013.11.002
  46. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci. 2007;10(9):1089-1093. doi: 10.1038/nn1971
  47. Guo X, Zhu Y, Guo L, et al. BCAA insufficiency leads to premature ovarian insufficiency via ceramide‐induced elevation of ROS. EMBO Mol Med. 2023;15(4):e17450. doi: 10.15252/emmm.202317450
  48. Gordon CM. Functional hypothalamic amenorrhea. N Engl J Med. 2010;363(4):365-371. doi: 10.1056/nejmcp0912024
  49. Gordon CM, Ackerman KE, Berga SL, et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(5):1413-1439. doi: 10.1210/jc.2017-00131
  50. Germain N, Fauconnier A, Klein JP, et al. Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight-recovered anorexia nervosa patients. Fertil Steril. 2017;107(2):502-509. doi: 10.1016/j.fertnstert.2016.10.032
  51. Kimball A, Sertic M, Saylor PJ, Kamran SC, Boyraz B. Case 38-2022: A 21-Year-Old Woman with Fatigue and Weight Gain. N Engl J Med. 2022;387(24):2269-2277. doi: 10.1056/nejmcpc2201250
  52. Yoshiji S, Shibue K, Fujii T, et al. Chronic primary adrenal insufficiency after unilateral adrenonephrectomy. Medicine. 2017;96(51):e9091. doi: 10.1097/md.0000000000009091
  53. Machura P, Grymowicz M, Rudnicka E, et al. Premature ovarian insufficiency – hormone replacement therapy and management of long-term consequences. Prz Menopauzalny. 2018;17(3):135-138. doi: 10.5114/pm.2018.78559
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept